CoChat
Sign Up
Cited by 166

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

Rossi, J-F, Négrier, S, James, N D, Kocak, I, Hawkins, R, Davis, H, Prabhakar, U, Qin, X, Mulders, P, Berns, B·2010·British Journal of Cancer
DOI 10.1038/sj.bjc.6605872PMC PMC2967052
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6605872

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CONSORT diagram for the randomised part 2.
Figure 1 CONSORT diagram for the randomised part 2.CC BY · PubMed Central
Figure 2 Kaplan–Meier plot of the time to disease progression through the end of study for treated patients in (A) part 2 and (B) part 3.
Figure 2 Kaplan–Meier plot of the time to disease progression through the end of study for treated patients in (A) part 2 and (B) part 3.CC BY · PubMed Central
Figure 3 Maximal percentage of tumour reduction according to modified WHO criteria for patients in parts 2 and 3. Dotted lines at 25% and −25% represent the criteria for PD and PR, respectively. Two patients in the 3 mg kg–1 group in part 2 were not evaluable because neither had a week 11 radiologic assessment.
Figure 3 Maximal percentage of tumour reduction according to modified WHO criteria for patients in parts 2 and 3. Dotted lines at 25% and −25% represent the criteria for PD and PR, respectively. Two patients in the 3 mg kg–1 group in part 2 were not evaluable because neither had a week 11 radiologic assessment.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 31

  1. Altundag O, Altundag K, Gunduz E (2005) Interleukin-6 and C-reactive protein in metastatic renal cell carcinoma. J Clin Oncol 23: 1044; author reply 1044-1045 · DOI
  2. Atzpodien J, Royston P, Wandert T, Reitz M (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88: 348–353 · DOI
  3. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM, Moskovtchenko JF, Philip T, Favrot M (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317–3322
  4. Blay JY, Rossi JF, Wijdenes J, Menetrier-Caux C, Schemann S, Negrier S, Philip T, Favrot M (1997) Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 72: 424–430 · DOI
  5. Cella D, Yount S, Du H, Dhanda R, Gondek K, Langefeld K, George J, Bro WP, Kelly C, Bukowski R (2006) Development and validation of the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). J Support Oncol 4: 191–199
  6. Chung YC, Chang YF (2003) Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol 15: 369–373 · DOI
  7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007a) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125–134 · DOI
  8. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007b) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370: 2103–2111 · DOI
  9. Fumagalli L, Lissoni P, Di Felice G, Meregalli S, Valsuani G, Mengo S, Rovelli F (1999) Pretreatment serum markers and lymphocyte response to interleukin-2 therapy. Br J Cancer 80: 407–411 · DOI
  10. Glaspy JA (2002) Therapeutic options in the management of renal cell carcinoma. Semin Oncol 29: 41–46 · DOI
  11. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271–2281 · DOI
  12. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110: 1241–1247 · DOI
  13. Kim HL, Belldegrun AS, Freitas DG, Bui MH, Han KR, Dorey FJ, Figlin RA (2003) Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol 170: 1742–1746 · DOI
  14. Legouffe E, Liautard J, Gaillard JP, Rossi JF, Wijdenes J, Bataille R, Klein B, Brochier J (1994) Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6. Clin Exp Immunol 98: 323–329 · DOI
  15. Ljungberg B, Grankvist K, Rasmuson T (1997) Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 33: 1794–1798 · DOI
  16. Lu ZY, Brailly H, Wijdenes J, Bataille R, Rossi JF, Klein B (1995) Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood 86: 3123–3131 · DOI
  17. Mahmoud FA, Rivera NI (2002) The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep 4: 250–255 · DOI
  18. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454–463 · DOI
  19. Motzer RJ, Bukowski RM (2006) Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol 24: 5601–5608 · DOI
  20. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356: 115–124 · DOI
  21. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, Ravaud A, Douillard JY, Chevreau C, Lasset C, Blay JY (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d’Immunotherapie. J Clin Oncol 22: 2371–2378 · DOI
  22. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 85: 765–771 · DOI
  23. Puchalski T, Prabhakar U, Jiao T, Berns B, Davis HM (2010) Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16: 1652–1661 · DOI
  24. Rossi JF, Legouffe E, Blay JY, Fabbro M, Mousseau M, Khenifar B, Negrier S, Liautard J, Mao LQ, Racadot E, Wijdenes J, Philip T, Brochier J, Klein B (1992) Hematological effects of in vivo blocking interleukin-6 (IL-6) with BE-8, a monoclonal antibody (MoAb) anti-IL-6. Blood 80: 432a
  25. Schips L, Lipsky K, Zigeuner R, Salfellner M, Winkler S, Langner C, Rehak P, Pummer K, Hubmer G (2003) Impact of tumor-associated symptoms on the prognosis of patients with renal cell carcinoma: a single-center experience of 683 patients. Urology 62: 1024–1028 · DOI
  26. Tanaka M, Kishimura M, Ozaki S, Osakada F, Hashimoto H, Okubo M, Murakami M, Nakao K (2000) Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J Clin Invest 106: 137–144 · DOI
  27. van Zaanen HC, Koopmans RP, Aarden LA, Rensink HJ, Stouthard JM, Warnaar SO, Lokhorst HM, van Oers MH (1996) Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop. J Clin Invest 98: 1441–1448 · DOI
  28. van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, van Oers MH (1998) Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 102: 783–790 · DOI
  29. Weissglas M, Schamhart D, Lowik C, Papapoulos S, Vos P, Kurth KH (1995) Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 153: 854–857 · DOI
  30. Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J, Wan B, Kwak LW, Yu L, Yi Q (2007) Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 12: 252–265 · DOI
  31. Zaki MH, Nemeth JA, Trikha M (2004) CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 111: 592–595 · DOI

Cited by

Sorted by citations

See all 166

Metadata

Authors
Rossi, J.-F., Négrier, S., James, N. D., Kocak, I., Hawkins, R., Davis, H., Prabhakar, U., Qin, X., Mulders, P., & Berns, B.
Venue
British Journal of Cancer
Publisher
Springer Science and Business Media LLC
Published
2010-08-31
Volume
103
Issue
8
Pages
1154-1162
ISSN
  • 0007-0920
  • 1532-1827
DOI
10.1038/sj.bjc.6605872
PMC
PMC2967052
Cited by
166
References
1
Language
en
Licence
www.springer.com/tdm (unspecified)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review